Klin Padiatr 2020; 232(02): 96
DOI: 10.1055/s-0040-1701860
PW I-V
Guided Poster Walk
© Georg Thieme Verlag KG Stuttgart · New York

Hodgkin lymphoma: results observed in an oncological center of the Ecuadorian Andes. Series of cases with follow-up

EI Guerrero
1   SOLCA, SOLCA Cuenca, Cuenca, Ecuador
2   Universidad, Universidad deCuenca, Cuenca, Ecuador
3   Universidad, Universidad de La Frontera, Temuco, Chile
,
R Alvarado
1   SOLCA, SOLCA Cuenca, Cuenca, Ecuador
,
C Manterola
3   Universidad, Universidad de La Frontera, Temuco, Chile
,
A Urdiales
1   SOLCA, SOLCA Cuenca, Cuenca, Ecuador
2   Universidad, Universidad deCuenca, Cuenca, Ecuador
,
L Albarracin
4   Centro Medico, Servicios Medicos Integrales, Cuenca, Ecuador
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2020 (online)

 
 

    Introduction Hodgkin lymphoma (HL) is a clonal, lymphoproliferative cell neoplasm which mainly involves nodes with high chances of survival (SV).

    Objective To determine differences in global survival (GS) and disease-free SV (DFSV) at 20 years according to risk.

    Methods Case series with follow-up. Patients with HL from 1 to 18 years old, treated at the Institute of SOLCA-Cuenca (1999-2019) were included. The outcome variables were: histology, symptoms, stage, risk, complete remission (CR), GS and DFSV. Once their treatments were completed, patients underwent clinical follow-up. Descriptive statistics (measures of central tendency and dispersion) and analytical (Chi2, Fisher exact and continuity correction) were used. SV analyzes were performed with Kaplan Meier and log-rank curves.

    Results

    Results: 44 patients (56.8% men) were studied, with a median age of 9.8 years. 45.5% had mixed cellularity and 63.6% presented symptoms B. Stage IV (31.8%) and high risk (56.8%) were the most frequent. After the first line of treatment, 32 patients (72.7%) achieved CR. The GS and DFSV at 20 years were 77.5% and 71.1% respectively. When comparing the subgroups according to risk, the GAVS and DFSV for patients with low, intermediate and high risk were 100%, 37.5 % and 85.7% (p = 0.167); and of 100%, 90.9% and 53.1% (p=0.358) respectively.

    Conclusion The GS and DFSV verified are similar to those reported in other studies. There were no differences between them and the patient’s risk.


    #

    Conflict of Interest:

    The authors declare no conflicts of interest